Corporate Partnerships
We’re working together with our corporate partners to continually improve the supportive care of people with cancer. Below are some of the opportunities for your company to partner with MASCC:
Sponsor Our Annual Meeting
As the pre-eminent international and interdisciplinary conference on supportive care in cancer, the MASCC/ISOO Annual Meeting is a prime opportunity for your company to showcase products and treatments used to prevent and manage the adverse effects of cancer. For more information on sponsorship opportunities at the MASCC/ISOO Annual Meeting, please contact Melissa Chin, MASCC Executive Director, at mchin@mascc.org or Ruxandra Nedu, MASCC Associate Director, at rnedu@mascc.org.Corporate MASCC Membership
Corporate MASCC membership brings a variety of benefits, including exclusive privileges at the MASCC/ISOO Annual Meeting. These include:- Opportunities to meet exclusively with key MASCC opinion leaders
- Priority in the selection of dates for educational initiatives for MASCC members
- Priority in the selection of time slots for satellite symposia held in conjunction with the MASCC/ISOO Annual Meeting
- Six 2-year MASCC memberships with online access to Supportive Care in Cancer
- Discounted rates to the MASCC/ISOO Annual Meeting
- Significantly reduced costs for reviews of corporate-developed educational materials with commentary from MASCC specialists
- Opportunities to work with key MASCC opinion leaders to look at site-specific symptoms and prevention and management of treatment-induced side effects in cancer
- Advanced knowledge of the topics and issues facing MASCC members through the work of the study groups
Corporate Premium Members:
Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.janssen.com/johnson-johnson-innovative-medicine. Follow us at @JanssenUS and @JNJInnovMed. Janssen Research & Development, LLC, and Janssen Biotech, Inc., are both Johnson & Johnson companies.
La Roche-Posay
For more than 15 years, La Roche-Posay has strived closely with dermatologists around the world, continually updating the scientific knowledge about skin side effects and providing safety-tested and efficient skincare solutions.
In 2023, La Roche-Posay gathered an international committee of experts (ISKIMO Board) including dermatologists, oncologists, radiotherapists, and nurses. By integrating all new oncology drugs while considering the unique characteristics of different skin colors, this collaboration generated an international dermocosmetic and drug algorithm (an atlas of solutions, available to healthcare professionals worldwide) to prevent and treat various skin side effects of cancer treatments.
In Addition, our program “Fight with Care” raises awareness on skin side effects and trains healthcare professionals and the general public to help patients, in addition to providing financial support and product donations.
For more information, please visit our website https://www.laroche-posay.com/
Corporate Members:
Napo Pharmaceuticals
Napo Pharmaceuticals, a wholly owned subsidiary of Jaguar Health, focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. For more information about Napo Pharmaceuticals, please visit www.napopharma.com.
RiboX Therapeutics
RiboX is a globally operated biotech, dedicated to discovering and developing fully engineered circular RNA therapeutics, cofounded by Drs. Ling-Ling Chen, Dan Peer and Weiyi Zhang in 2021. The company has operations in Princeton, NJ, USA, Rehovot, Israel and Shanghai, China. Circular RNA therapy is a novel modality, which is considered as the next generation RNA therapy. Compared to mRNA, circular RNA has a covalently closed single-stranded RNA structure that confers superior stability, lowers immunogenicity, and tunable protein expression, subsequently overcoming the current limitations of mRNA therapeutics and realizing the full potential of RNA medicines.
RiboX has developed proprietary plug-and-play circular RNA drug design and engineering, combined with novel LNPs platforms and robust manufacturing capabilities. These innovative technologies provide support for the clinical development of circular RNA therapeutics. RiboX’s pipeline spans various therapeutic areas, including radiation-induced xerostomia, monogenic diseases, autoimmune diseases, and vaccines. RiboX is committed to pioneering innovative research in next-generation RNA therapies, with a vision to improve the quality of life for patients worldwide.
For further information, please visit: https://www.riboxtx.com
To learn more about RiboX’s recent study, please visit: www.riboxtx.com/sprinx-1
Media contact: bd@ribox-tx.com
